Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Altor on acquisition of Palette Software
Mandate

Vinge advises Altor on acquisition of Palette Software

July 02, 2021 Employment and Benefits M&A IT, Telecommunications and Outsourcing

Vinge is advising Altor Fund V (“Altor”) in its acquisition of a majority stake in Palette Software AB (“Palette”). Altor acquires the company from previous owner Monterro, founders and management. The ambition is to accelerate investments in growing Palette into one of the leading accounts payable automation software providers globally.

Palette is an Accounts Payable automation (AP Automation) software company offering procure-to-pay and digital invoice processing solutions for the SME and mid-market segments. The company, which has 120 employees and is headquartered in Stockholm, has more than 1,500 customers predominantly in Sweden and Finland. Palette has annual recurring revenue (ARR) of approximately 200 MSEK.

The Vinge team advising Altor includes partner Christina Kokko and associates Carl Sander, Vilhelm Rondahl, Elsie Nassar and Nando Basic (M&A), Mathilda Persson and Lisa Hörnqvist (IT), Carl Östlund (Employment), and VDR-specialist Sara Dahlros Sköld.

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

 Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025